Poul Strange
Poul Strange has extensive experience in the scientific and medical disciplines of the pharmaceutical industry where he has held positions ranging from drug discovery, clinical pharmacology and phase 2 and 3 clinical development through medical affairs including responsibility for biometrics and pharmacoeconomics. Data gathering, handling, analysis and reporting experience includes pre-clinical experiments, clinical pharmacology, registration trials, and medical affairs trials up to thousands of patients, health outcomes trials including patient reported outcomes, naturalistic trials, registries and retrospective analysis of large databases. He holds an M.D. and a Ph.D. in Immunology from the University of Copenhagen, as well as a Business Diploma in International Trade from Copenhagen Business School. He joined industry as a Medical Adviser for Growth Hormone in Novo Nordisk, Denmark; and has since held positions as Therapeutic Area Leader, Inflammation in ZymoGenetics, WA;  various development positions in Novo Nordisk, NJ, the last one being Senior Director, Drug Development for therapeutic areas Diabetes, Coagulation Disorders, Female Health. He joined Aventis in 2000 as Therapeutic Area Leader for US Metabolism Medical Research and headed up all medical affairs activities in diabetes within the United States from year 2003 to 2006 including the time of transition from the Sanofi acquisition of Aventis. Since then Poul Strange has worked as an independent consultant to the the biotech, device and pharmaceutical industries originally through Integrated Medical Development that he founded in 2006, and now through Phase 1 to 4 that he founded in 2009.